Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 15/20 | 0.46 |
| ▸ | HTR1A | P08908 | 11/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.46 |
| ▸ | RHEB | Q15382 | 2/20 | 0.39 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22651010 | 0.85 | DPP4 (0.49) | SLC6A2HTR1ASLC6A3SLC6A4ALDH1A1 | |
| SCHEMBL5405309 | 0.81 | NFE2L2 (0.47) | ALDH1A1 | |
| SCHEMBL5405305 | 0.81 | SLC6A2 (0.36) | SLC6A2HTR1ASLC6A3SLC6A4RHEB | |
| SCHEMBL11541852 | 0.80 | PARP10 (0.36) | SLC6A2HTR1ASLC6A3SLC6A4ALDH1A1 | |
| SCHEMBL14237478 | 0.79 | SLC6A2 (0.33) | SLC6A2HTR1ASLC6A3SLC6A4TAAR1 | |
| SCHEMBL1042133 | 0.78 | — | — | |
| SCHEMBL19176364 | 0.76 | CA1 (0.49) | SLC6A2HTR1ASLC6A3SLC6A4ALDH1A1 | |
| SCHEMBL30604502 | 0.76 | SLC6A2 (0.33) | SLC6A2HTR1ASLC6A3SLC6A4RHEB | |
| SCHEMBL2885551 | 0.76 | L3MBTL1 (0.55) | ALDH1A1 | |
| Phosphine SCHEMBL28191581 | 0.75 | TAAR1 (0.41) | SLC6A2HTR1ASLC6A3SLC6A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140288040-A1 | SUBSTITUTED BENZYLAMINE COMPOUNDS, THEIR USE IN MEDICINE, AND IN PARTICULAR THE TREATMENT OF HEPATITIS C VIRUS (HCV) INFECTION | ASTEX THERAPEUTICS LIMITED (GB) | 2014-09-25 | — | — | US | disclosed |
| EP-2773613-A1 | SUBSTITUTED BENZYLAMINE COMPOUNDS, THEIR USE IN MEDICINE, AND IN PARTICULAR THE TREATMENT OF HEPATITIS C VIRUS (HCV) INFECTION | Astex Therapeutics Limited (GB) | 2014-09-10 | — | — | EP | disclosed |
| WO-2013064538-A1 | SUBSTITUTED BENZYLAMINE COMPOUNDS, THEIR USE IN MEDICINE, AND IN PARTICULAR THE TREATMENT OF HEPATITIS C VIRUS (HCV) INFECTION | ASTEX THERAPEUTICS LIMITED (GB) | 2013-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288040-A1 | SUBSTITUTED BENZYLAMINE COMPOUNDS, THEIR USE IN MEDICINE, AND IN PARTICULAR THE TREATMENT OF HEPATITIS C VIRUS (HCV) INFECTION | NR1H4, CFH, SLC10A1 | SLC6A2 143/4885HTR1A 891/4885SLC6A3 335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.